

**NOTICE OF NEW HAMPSHIRE MEDICAID FEE FOR SERVICE
DRUG UTILIZATION REVIEW BOARD
PUBLIC HEARING
May 7, 2024**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 1:00 p.m., on May 7, 2024 in the Brown Building Conference Room 468 **and** via Teams Webinar. The DUR meeting will immediately follow this public hearing. The Teams Webinar information will be available 1 week prior to the DUR meeting at <https://nh.magellanrx.com/>.

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid Fee for Service pharmacy prior authorization criteria and PDL additions.

The public hearing will begin at 1:00 p.m. and end no later than 2:00 p.m. The DUR meeting will begin at or before 2:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the proposed prior authorization criteria and PDL additions. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda.

Written material may also be submitted by the public for DUR Board consideration, if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

If accommodations are needed for communication access such as interpreters, CART (captioning), assistive listening devices, or other auxiliary aids and/or services, please contact Margaret 'Peg' Clifford at (603) 271-9098 by April 23, 2024. At least 5 business days advance notice is requested in order to assure availability; requests made fewer than 5 days prior to the event will attempt to be accommodated but cannot be guaranteed.

**DRUG UTILIZATION REVIEW BOARD MEETING
May 7, 2024
Meeting Agenda**

- I. Introductions and Welcome to Board Members

- II. Old Business
 - A. Minutes – 12/8/2023 review

- III. New Business
 - A. DUR Business Operations
 - 1. Overview of Drug Utilization Patterns for the New Hampshire Medicaid Fee-for Service Program
 - a. Prospective DUR Reports
 - b. Utilization Reports
 - c. Retrospective DUR Reports

B. COVID-19 Status Update

C. Review of Current Clinical Prior Authorization Criteria with Proposed Changes

1. Asthma/Allergy Immunomodulator
2. Drugs for Bowel Disorders/GI Motility, Chronic
3. Calcitonin Gene-Related Peptide (CGRP) Inhibitor
4. CNS Stimulant and ADHD/ADD
5. Skin Disorders
6. Spinal Muscular Atrophy
7. Systemic Immunomodulators
8. Weight Management

D. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes

1. Buprenorphine/Naloxone and Buprenorphine Oral
2. Duchenne Muscular Dystrophy
3. Hematopoietic Agent
4. Short Acting Fentanyl
5. Skysona®
6. Zynteglo™

E. Proposal of New Clinical Prior Authorization Criteria

1. Casgevy™
2. Lenmeldy™
3. Lyfgenia™
4. Rezdiffra™
5. Wakix®
6. Zurzuvae™

F. Proposal of New Preferred Drug List (PDL) Category

1. Duchenne Muscular Dystrophy
2. Sickle Cell Gene Therapy
3. Spinal Muscular Atrophy

IV. Adjourn

Further information regarding the agenda items may be obtained after April 23, 2024. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Margaret 'Peg' Clifford, NH Department of Health and Human Services, 129 Pleasant Street, Concord, NH, 03301, (603) 271-9098, or e-mail at: margaret.clifford@dhhs.nh.gov.